Eric P. Hanson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Eric P. Hanson has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Jordan S. Orange
Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, Columbia University, New York, NY
6 shared publications - Alex W. Wessel
Immunodeficiency and Inflammatory Disease Unit and
2 shared publications Ashish Jain
Laboratory of Host Defenses, Clinical Immunology Unit, National Institute of Allergy and Infectious Diseases Bethesda, MD, USA
2 shared publicationsGulbu Uzel
Immunopathogenesis Section, Laboratory of Clinical Infectious Diseases, 8Laboratory of Allergic Diseases, 9Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases; 10National Center for Biotechnology Information; 11National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Insitutes of Health, Bethesda, MD 20892
2 shared publicationsJames A. Johnston
DNAX Research Institute, 901 California Avenue, Palo Alto, CA, 94304, USA
2 shared publications- Jevgenia Zilberman-Rudenko
Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California, USA; Departments of Biomedical Engineering and Medicine, School of Medicine, Oregon Health & Science University, Portland, Oregon, USA
2 shared publications
Latest Publications
- Open Access
- 6 March 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (3) , e70519
Early Development of Ocadusertib, a Selective Receptor‐Interacting Serine/Threonine‐Protein Kinase 1 Inhibitor
Receptor‐interacting serine/threonine‐protein kinase 1 (RIPK1) inhibitors are being investigated for chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Ocadusertib is a potent and selective allosteric inhibitor of RIPK1 and is currently being studied in clinical trials. Here, we present data on the development of ocadusertib, including preclinical studies and pharmacokinetic, safety, and target engagement results from phase 1 trials. Preclinically, ocadusertib inhibited RIPK1 enzymatic activity with high potency (half‐maximal inhibitory concentration [IC 50 ] = 12–38 nM) and inhibited necroptotic responses in multiple cell‐based assays. Ocadusertib was highly selective for RIPK1, showing no significant inhibition of more than 100 other kinases representative of the full kinome. In mouse studies, ocadusertib treatment prevented RIPK1‐dependent hypothermia in response to tumor necrosis factor (TNF) challenge and significantly reduced disease severity in a model of chronic proliferative dermatitis. In a first‐in‐human study of ocadusertib in healthy participants, single oral doses exhibited linear pharmacokinetics and dose‐proportional exposure, with a time to maximum concentration of 1–4 h and a half‐life of 13–15 h. Steady state was attained at 4–6 days after multiple once‐daily dose administrations. Ocadusertib was well tolerated, with no deaths, serious adverse events, or significant treatment‐emergent adverse events reported. In a phase 1, double‐blind, randomized, multiple‐dose study in healthy participants, greater than 90% RIPK1 target engagement was achieved at Day 14 with ocadusertib treatment. Taken together, these findings support further assessment of ocadusertib for the treatment of chronic inflammatory diseases.
- 6 March 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (3) , e70519
Open AccessEarly Development of Ocadusertib, a Selective Receptor‐Interacting Serine/Threonine‐Protein Kinase 1 Inhibitor
Receptor‐interacting serine/threonine‐protein kinase 1 (RIPK1) inhibitors are being investigated for chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Ocadusertib is a potent and selective allosteric inhibitor of RIPK1 and is currently being studied in clinical trials. Here, we present data on the development of ocadusertib, including preclinical studies and pharmacokinetic, safety, and target engagement results from phase 1 trials. Preclinically, ocadusertib inhibited RIPK1 enzymatic activity with high potency (half‐maximal inhibitory concentration [IC 50 ] = 12–38 nM) and inhibited necroptotic responses in multiple cell‐based assays. Ocadusertib was highly selective for RIPK1, showing no significant inhibition of more than 100 other kinases representative of the full kinome. In mouse studies, ocadusertib treatment prevented RIPK1‐dependent hypothermia in response to tumor necrosis factor (TNF) challenge and significantly reduced disease severity in a model of chronic proliferative dermatitis. In a first‐in‐human study of ocadusertib in healthy participants, single oral doses exhibited linear pharmacokinetics and dose‐proportional exposure, with a time to maximum concentration of 1–4 h and a half‐life of 13–15 h. Steady state was attained at 4–6 days after multiple once‐daily dose administrations. Ocadusertib was well tolerated, with no deaths, serious adverse events, or significant treatment‐emergent adverse events reported. In a phase 1, double‐blind, randomized, multiple‐dose study in healthy participants, greater than 90% RIPK1 target engagement was achieved at Day 14 with ocadusertib treatment. Taken together, these findings support further assessment of ocadusertib for the treatment of chronic inflammatory diseases.
- Open Access
- 31 March 2020
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (5)
Somatic SMAD3-activating mutations cause melorheostosis by up-regulating the TGF-β/SMAD pathway
Melorheostosis is a rare sclerosing dysostosis characterized by asymmetric exuberant bone formation. Recently, we reported that somatic mosaicism for MAP2K1-activating mutations causes radiographical “dripping candle wax” melorheostosis. We now report somatic SMAD3 mutations in bone lesions of four unrelated patients with endosteal pattern melorheostosis. In vitro, the SMAD3 mutations stimulated the TGF-β pathway in osteoblasts, enhanced nuclear translocation and target gene expression, and inhibited proliferation. Osteoblast differentiation and mineralization were stimulated by the SMAD3 mutation, consistent with higher mineralization in affected than in unaffected bone, but differing from MAP2K1 mutation–positive melorheostosis. Conversely, osteoblast differentiation and mineralization were inhibited when osteogenesis of affected osteoblasts was driven in the presence of BMP2. Transcriptome profiling displayed that TGF-β pathway activation and ossification-related processes were significantly influenced by the SMAD3 mutation. Co-expression clustering illuminated melorheostosis pathophysiology, including alterations in ECM organization, cell growth, and interferon signaling. These data reveal antagonism of TGF-β/SMAD3 activation by BMP signaling in SMAD3 mutation–positive endosteal melorheostosis, which may guide future therapies.
- 31 March 2020
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 217 (5)
Open AccessSomatic SMAD3-activating mutations cause melorheostosis by up-regulating the TGF-β/SMAD pathway
Melorheostosis is a rare sclerosing dysostosis characterized by asymmetric exuberant bone formation. Recently, we reported that somatic mosaicism for MAP2K1-activating mutations causes radiographical “dripping candle wax” melorheostosis. We now report somatic SMAD3 mutations in bone lesions of four unrelated patients with endosteal pattern melorheostosis. In vitro, the SMAD3 mutations stimulated the TGF-β pathway in osteoblasts, enhanced nuclear translocation and target gene expression, and inhibited proliferation. Osteoblast differentiation and mineralization were stimulated by the SMAD3 mutation, consistent with higher mineralization in affected than in unaffected bone, but differing from MAP2K1 mutation–positive melorheostosis. Conversely, osteoblast differentiation and mineralization were inhibited when osteogenesis of affected osteoblasts was driven in the presence of BMP2. Transcriptome profiling displayed that TGF-β pathway activation and ossification-related processes were significantly influenced by the SMAD3 mutation. Co-expression clustering illuminated melorheostosis pathophysiology, including alterations in ECM organization, cell growth, and interferon signaling. These data reveal antagonism of TGF-β/SMAD3 activation by BMP signaling in SMAD3 mutation–positive endosteal melorheostosis, which may guide future therapies.
- 22 January 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (6) , 1612-1617
Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-κB activation and autoinflammatory disease
Significance: Regulated activation of the NF-κB family of transcription factors is important for normal development, immune cell function, and inflammatory responses. NEMO, the NF-κB essential modulator, controls activation of the canonical IKK complex and NF-κB–mediated cellular responses, but details of how this is achieved are not fully known. Our results show that C-terminal mutations in NEMO can cause hyperactivation of inflammatory responses to Toll-like receptor and TNF ligands through impaired recruitment of the negative NF-κB regulator A20/TNFAIP3. Our results help to explain the inflammatory symptoms in patients harboring these NEMO mutations. Furthermore, our findings suggest that targeting this molecular interaction by enhancing A20 expression or its recruitment to the NEMO C-terminus may be a therapeutic strategy for human inflammatory disease.
- 22 January 2016
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 113 (6) , 1612-1617
Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-κB activation and autoinflammatory disease
Significance: Regulated activation of the NF-κB family of transcription factors is important for normal development, immune cell function, and inflammatory responses. NEMO, the NF-κB essential modulator, controls activation of the canonical IKK complex and NF-κB–mediated cellular responses, but details of how this is achieved are not fully known. Our results show that C-terminal mutations in NEMO can cause hyperactivation of inflammatory responses to Toll-like receptor and TNF ligands through impaired recruitment of the negative NF-κB regulator A20/TNFAIP3. Our results help to explain the inflammatory symptoms in patients harboring these NEMO mutations. Furthermore, our findings suggest that targeting this molecular interaction by enhancing A20 expression or its recruitment to the NEMO C-terminus may be a therapeutic strategy for human inflammatory disease.
- Top Cited PapersOpen Access
- 7 December 2015
- Published by Springer Nature in Nature Genetics
- Vol. 48 (1) , 67-73
Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease
Ivona Aksentijevich and colleagues identify heterozygous loss-of-function mutations in TNFAIP3 (encoding A20) in six unrelated families with early-onset systemic inflammation. Affected individuals exhibit increased expression of NF-κB–mediated proinflammatory cytokines, consistent with the established role of A20 as a potent inhibitor of the NF-κB signaling pathway. Systemic autoinflammatory diseases are driven by abnormal activation of innate immunity1. Herein we describe a new disease caused by high-penetrance heterozygous germline mutations in TNFAIP3, which encodes the NF-κB regulatory protein A20, in six unrelated families with early-onset systemic inflammation. The disorder resembles Behçet's disease, which is typically considered a polygenic disorder with onset in early adulthood2. A20 is a potent inhibitor of the NF-κB signaling pathway3. Mutant, truncated A20 proteins are likely to act through haploinsufficiency because they do not exert a dominant-negative effect in overexpression experiments. Patient-derived cells show increased degradation of IκBα and nuclear translocation of the NF-κB p65 subunit together with increased expression of NF-κB–mediated proinflammatory cytokines. A20 restricts NF-κB signals via its deubiquitinase activity. In cells expressing mutant A20 protein, there is defective removal of Lys63-linked ubiquitin from TRAF6, NEMO and RIP1 after stimulation with tumor necrosis factor (TNF). NF-κB–dependent proinflammatory cytokines are potential therapeutic targets for the patients with this disease.
- 7 December 2015
- Published by Springer Nature in Nature Genetics
- Vol. 48 (1) , 67-73
Top Cited PapersOpen AccessLoss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease
Ivona Aksentijevich and colleagues identify heterozygous loss-of-function mutations in TNFAIP3 (encoding A20) in six unrelated families with early-onset systemic inflammation. Affected individuals exhibit increased expression of NF-κB–mediated proinflammatory cytokines, consistent with the established role of A20 as a potent inhibitor of the NF-κB signaling pathway. Systemic autoinflammatory diseases are driven by abnormal activation of innate immunity1. Herein we describe a new disease caused by high-penetrance heterozygous germline mutations in TNFAIP3, which encodes the NF-κB regulatory protein A20, in six unrelated families with early-onset systemic inflammation. The disorder resembles Behçet's disease, which is typically considered a polygenic disorder with onset in early adulthood2. A20 is a potent inhibitor of the NF-κB signaling pathway3. Mutant, truncated A20 proteins are likely to act through haploinsufficiency because they do not exert a dominant-negative effect in overexpression experiments. Patient-derived cells show increased degradation of IκBα and nuclear translocation of the NF-κB p65 subunit together with increased expression of NF-κB–mediated proinflammatory cytokines. A20 restricts NF-κB signals via its deubiquitinase activity. In cells expressing mutant A20 protein, there is defective removal of Lys63-linked ubiquitin from TRAF6, NEMO and RIP1 after stimulation with tumor necrosis factor (TNF). NF-κB–dependent proinflammatory cytokines are potential therapeutic targets for the patients with this disease.
- 1 February 2015
- Published by Springer Nature
- Vol. 1280, 413-426
A Method for the Quantitative Analysis of Stimulation-Induced Nuclear Translocation of the p65 Subunit of NF-κB from Patient-Derived Dermal Fibroblasts
Developmental and immune-mediated disease has been linked to genetic mutation of key signaling components involved in NF-κB activation that leads to impaired activation or regulation of the canonical IKK complex. We identify patients with suspected or known defects of the NF-κB signaling pathway through clinical phenotyping and genetic sequencing. To help understand how mutations cause disease, we quantitate the kinetics and dose-response of NF-κB activation signaling events in their cells. Following activation of the canonical IKK complex, phosphorylation of the inhibitor of NF-κB proteins (IκB) leads to their degradation and the subsequent translocation of NF-κB family members from the cell cytoplasm to the nucleus. Here, we provide a method to obtain patient-derived dermal fibroblasts and quantitatively assess the integrity of the signal transduction pathway from receptor activation to nuclear p65 translocation.
- 1 February 2015
- Published by Springer Nature
- Vol. 1280, 413-426
A Method for the Quantitative Analysis of Stimulation-Induced Nuclear Translocation of the p65 Subunit of NF-κB from Patient-Derived Dermal Fibroblasts
Developmental and immune-mediated disease has been linked to genetic mutation of key signaling components involved in NF-κB activation that leads to impaired activation or regulation of the canonical IKK complex. We identify patients with suspected or known defects of the NF-κB signaling pathway through clinical phenotyping and genetic sequencing. To help understand how mutations cause disease, we quantitate the kinetics and dose-response of NF-κB activation signaling events in their cells. Following activation of the canonical IKK complex, phosphorylation of the inhibitor of NF-κB proteins (IκB) leads to their degradation and the subsequent translocation of NF-κB family members from the cell cytoplasm to the nucleus. Here, we provide a method to obtain patient-derived dermal fibroblasts and quantitatively assess the integrity of the signal transduction pathway from receptor activation to nuclear p65 translocation.
- 31 October 2014
- Published by Elsevier
- p. 113-118
Signal transduction in immune cells
- Open Access
- 25 February 2013
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 210 (3) , 433-443
Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome
Primary immunodeficiencies (PIDs) represent exquisite models for studying mechanisms of human host defense. In this study, we report on two unrelated kindreds, with two patients each, who had cryptosporidial infections associated with chronic cholangitis and liver disease. Using exome and candidate gene sequencing, we identified two distinct homozygous loss-of-function mutations in the interleukin-21 receptor gene (IL21R; c.G602T, p.Arg201Leu and c.240_245delCTGCCA, p.C81_H82del). The IL-21RArg201Leu mutation causes aberrant trafficking of the IL-21R to the plasma membrane, abrogates IL-21 ligand binding, and leads to defective phosphorylation of signal transducer and activator of transcription 1 (STAT1), STAT3, and STAT5. We observed impaired IL-21–induced proliferation and immunoglobulin class-switching in B cells, cytokine production in T cells, and NK cell cytotoxicity. Our study indicates that human IL-21R deficiency causes an immunodeficiency and highlights the need for early diagnosis and allogeneic hematopoietic stem cell transplantation in affected children.
- 25 February 2013
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 210 (3) , 433-443
Open AccessLoss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome
Primary immunodeficiencies (PIDs) represent exquisite models for studying mechanisms of human host defense. In this study, we report on two unrelated kindreds, with two patients each, who had cryptosporidial infections associated with chronic cholangitis and liver disease. Using exome and candidate gene sequencing, we identified two distinct homozygous loss-of-function mutations in the interleukin-21 receptor gene (IL21R; c.G602T, p.Arg201Leu and c.240_245delCTGCCA, p.C81_H82del). The IL-21RArg201Leu mutation causes aberrant trafficking of the IL-21R to the plasma membrane, abrogates IL-21 ligand binding, and leads to defective phosphorylation of signal transducer and activator of transcription 1 (STAT1), STAT3, and STAT5. We observed impaired IL-21–induced proliferation and immunoglobulin class-switching in B cells, cytokine production in T cells, and NK cell cytotoxicity. Our study indicates that human IL-21R deficiency causes an immunodeficiency and highlights the need for early diagnosis and allogeneic hematopoietic stem cell transplantation in affected children.
- 1 July 2011
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 107 (1) , 50-56
Congenital alterations of NEMO glutamic acid 223 result in hypohidrotic ectodermal dysplasia and immunodeficiency with normal serum IgG levels
- 1 July 2011
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 107 (1) , 50-56
Congenital alterations of NEMO glutamic acid 223 result in hypohidrotic ectodermal dysplasia and immunodeficiency with normal serum IgG levels
- Open Access
- 1 January 2011
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 2, 16178
Hypohidrotic Ectodermal Dysplasia and Immunodeficiency with Coincident NEMO and EDA Mutations
Ectodermal dysplasias (ED) are uncommon genetic disorders resulting in abnormalities in ectodermally derived structures. Many ED-associated genes have been described, of which ectodysplasin-A (EDA) is one of the more common. The NF-κB essential modulator (NEMO encoded by the IKBKG gene) is unique in that mutations result in severe humoral and cellular immunologic defects in addition to ED. We describe three unrelated kindreds with defects in both EDA and IKBKG resulting from X-chromosome crossover. This demonstrates the importance of thorough immunologic consideration of patients with ED even when an EDA etiology is confirmed, and raises the possibility of a specific phenotype arising from coincident mutations in EDA and IKBKG.
- 1 January 2011
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 2, 16178
Open AccessHypohidrotic Ectodermal Dysplasia and Immunodeficiency with Coincident NEMO and EDA Mutations
Ectodermal dysplasias (ED) are uncommon genetic disorders resulting in abnormalities in ectodermally derived structures. Many ED-associated genes have been described, of which ectodysplasin-A (EDA) is one of the more common. The NF-κB essential modulator (NEMO encoded by the IKBKG gene) is unique in that mutations result in severe humoral and cellular immunologic defects in addition to ED. We describe three unrelated kindreds with defects in both EDA and IKBKG resulting from X-chromosome crossover. This demonstrates the importance of thorough immunologic consideration of patients with ED even when an EDA etiology is confirmed, and raises the possibility of a specific phenotype arising from coincident mutations in EDA and IKBKG.